Published in AIDS Weekly, April 7th, 2003
"Amprenavir is a human immunodeficiency virus-1 (HIV-1) protease inhibitor intended to be used to treat HIV-infected children," researchers in France explained. "Although a pediatric dosage is proposed by the manufacturer, no data are currently available on the pharmacokinetics of amprenavir in neonates and infants."
Because the drug is "primarily eliminated after oxidative biotransformation," J. M. Treluyer and coauthors at the National Center for Scientific Research "explored its in vitro metabolism by cytochrome P450 (P450)-dependent monooxygenases."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.